PCDH8 is a novel prognostic biomarker in thyroid cancer and promotes cell proliferation and viability.

"Declarations Ethics approval and consent to participateThe Research Ethics Committee of The First Affiliated Hospital of Xi’an Jiaotong University has approved our research programme and process. All written informed consent was obtained from all individual participants included in the study. All procedures conducted in studies involving human participants were in accordance with the ethical standards of the Research Ethics Committee of The First Affiliated Hospital of Xi’an Jiaotong University and with the 1964 Helsinki declaration and its later amendments. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This study was supported by grants from the Natural Science Basic Research Program of Shaanxi (2020JC-36), the Research Foundation of the First Affiliated Hospital of Xi'an Jiaotong University (2021QN-01), and Fundamental Research Funds for the Central Universities (sxzy012022031)."